Fosamprenavir plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, while Amprenavir Exposure Remains Unchanged
- 1 August 2007
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (8) , 2982-2984
- https://doi.org/10.1128/aac.00008-07
Abstract
Plasma ketoconazole (KETO), amprenavir (APV), and ritonavir (RTV) pharmacokinetics were evaluated in 15 healthy subjects after being treated with KETO at 200 mg once daily (QD), fosamprenavir (FPV)/RTV at 700/100 mg twice daily (BID), and then KETO at 200 mg QD plus FPV/RTV at 700/100 mg BID in this open-label study. The KETO area under the concentration-time curve at steady state was increased 2.69-fold with FPV/RTV. APV exposure was unchanged, and RTV exposure was slightly increased.Keywords
This publication has 2 references indexed in Scilit:
- Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virusClinical Pharmacology & Therapeutics, 2000
- Pharmacokinetic Interaction between Ketoconazole and Amprenavir after Single Doses in Healthy MenPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1999